10x Genomics, Inc. — Director's Dealing 2020

May 5, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2020-05-01

Reporting Person: Saxonov Serge (Director, Chief Executive Officer, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-01	Class A Common Stock	M	833	$1.20	Acquired	955514	Direct
2020-05-01	Class A Common Stock	M	9167	$5.04	Acquired	964681	Direct
2020-05-01	Class A Common Stock	S	5301	$76.6533	Disposed	959380	Direct
2020-05-01	Class A Common Stock	S	2197	$77.6557	Disposed	957183	Direct
2020-05-01	Class A Common Stock	S	2502	$78.7224	Disposed	954681	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-01	Stock Option (right to buy)	$1.20	M	833	Disposed	2027-10-18	Class A Common Stock (833)	Direct
2020-05-01	Stock Option (right to buy)	$5.04	M	9167	Disposed	2028-11-02	Class A Common Stock (9167)	Direct

Footnotes

F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2: This transaction was executed in multiple trades at prices ranging from $76.19 to $77.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $77.23 to $78.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $78.39 to $79.20. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This option, originally for 300,000 shares, of which 168,750 have been exercised, vested as to one-forty-eighth of the shares on October 1, 2017, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F6: This option, originally for 250,000 shares, of which 76,875 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.